Barclays PLC Inmune Bio, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 29,044 shares of INMB stock, worth $130,407. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,044
Previous 29,044
-0.0%
Holding current value
$130,407
Previous $157,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding INMB
# of Institutions
71Shares Held
5.92MCall Options Held
243KPut Options Held
46.4K-
Black Rock Inc. New York, NY813KShares$3.65 Million0.0% of portfolio
-
Praetorian Pr LLC Rincon, PR781KShares$3.51 Million1.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA721KShares$3.24 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$2.68 Million45.87% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL369KShares$1.66 Million0.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $80.6M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...